Spain’s Grifols Takes Restructuring Route After COVID Challenges
Over 2,000 Jobs To Go In US
The Barcelona-based company is making major cuts to its headcount in a bid to save €400m and support its operational recovery after the significant impact of the pandemic to Grifol’s plasma business.
You may also be interested in...
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth
Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.
Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.